Cargando…
Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum
Protein homeostasis, or proteostasis, has an important regulatory role in cellular function. Protein quality control mechanisms, including protein folding and protein degradation processes, have a crucial function in post-mitotic neurons. Cellular protein quality control relies on multiple strategie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423993/ https://www.ncbi.nlm.nih.gov/pubmed/28539871 http://dx.doi.org/10.3389/fnmol.2017.00119 |
_version_ | 1783235041596276736 |
---|---|
author | Shahheydari, Hamideh Ragagnin, Audrey Walker, Adam K. Toth, Reka P. Vidal, Marta Jagaraj, Cyril J. Perri, Emma R. Konopka, Anna Sultana, Jessica M. Atkin, Julie D. |
author_facet | Shahheydari, Hamideh Ragagnin, Audrey Walker, Adam K. Toth, Reka P. Vidal, Marta Jagaraj, Cyril J. Perri, Emma R. Konopka, Anna Sultana, Jessica M. Atkin, Julie D. |
author_sort | Shahheydari, Hamideh |
collection | PubMed |
description | Protein homeostasis, or proteostasis, has an important regulatory role in cellular function. Protein quality control mechanisms, including protein folding and protein degradation processes, have a crucial function in post-mitotic neurons. Cellular protein quality control relies on multiple strategies, including molecular chaperones, autophagy, the ubiquitin proteasome system, endoplasmic reticulum (ER)-associated degradation (ERAD) and the formation of stress granules (SGs), to regulate proteostasis. Neurodegenerative diseases are characterized by the presence of misfolded protein aggregates, implying that protein quality control mechanisms are dysfunctional in these conditions. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diseases that are now recognized to overlap clinically and pathologically, forming a continuous disease spectrum. In this review article, we detail the evidence for dysregulation of protein quality control mechanisms across the whole ALS-FTD continuum, by discussing the major proteins implicated in ALS and/or FTD. We also discuss possible ways in which protein quality mechanisms could be targeted therapeutically in these disorders and highlight promising protein quality control-based therapeutics for clinical trials. |
format | Online Article Text |
id | pubmed-5423993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54239932017-05-24 Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum Shahheydari, Hamideh Ragagnin, Audrey Walker, Adam K. Toth, Reka P. Vidal, Marta Jagaraj, Cyril J. Perri, Emma R. Konopka, Anna Sultana, Jessica M. Atkin, Julie D. Front Mol Neurosci Neuroscience Protein homeostasis, or proteostasis, has an important regulatory role in cellular function. Protein quality control mechanisms, including protein folding and protein degradation processes, have a crucial function in post-mitotic neurons. Cellular protein quality control relies on multiple strategies, including molecular chaperones, autophagy, the ubiquitin proteasome system, endoplasmic reticulum (ER)-associated degradation (ERAD) and the formation of stress granules (SGs), to regulate proteostasis. Neurodegenerative diseases are characterized by the presence of misfolded protein aggregates, implying that protein quality control mechanisms are dysfunctional in these conditions. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diseases that are now recognized to overlap clinically and pathologically, forming a continuous disease spectrum. In this review article, we detail the evidence for dysregulation of protein quality control mechanisms across the whole ALS-FTD continuum, by discussing the major proteins implicated in ALS and/or FTD. We also discuss possible ways in which protein quality mechanisms could be targeted therapeutically in these disorders and highlight promising protein quality control-based therapeutics for clinical trials. Frontiers Media S.A. 2017-05-10 /pmc/articles/PMC5423993/ /pubmed/28539871 http://dx.doi.org/10.3389/fnmol.2017.00119 Text en Copyright © 2017 Shahheydari, Ragagnin, Walker, Toth, Vidal, Jagaraj, Perri, Konopka, Sultana and Atkin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Shahheydari, Hamideh Ragagnin, Audrey Walker, Adam K. Toth, Reka P. Vidal, Marta Jagaraj, Cyril J. Perri, Emma R. Konopka, Anna Sultana, Jessica M. Atkin, Julie D. Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title | Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title_full | Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title_fullStr | Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title_full_unstemmed | Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title_short | Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum |
title_sort | protein quality control and the amyotrophic lateral sclerosis/frontotemporal dementia continuum |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423993/ https://www.ncbi.nlm.nih.gov/pubmed/28539871 http://dx.doi.org/10.3389/fnmol.2017.00119 |
work_keys_str_mv | AT shahheydarihamideh proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT ragagninaudrey proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT walkeradamk proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT tothrekap proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT vidalmarta proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT jagarajcyrilj proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT perriemmar proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT konopkaanna proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT sultanajessicam proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum AT atkinjulied proteinqualitycontrolandtheamyotrophiclateralsclerosisfrontotemporaldementiacontinuum |